CRT is formed through the merger of Cancer Research Ventures and Imperial Cancer Research Technology

Cancer Research UK today (Wednesday, October 2, 2002) announces its new technology transfer company with a remit to exploit the fruits of its world class research programme into preventative strategies, diagnostic kits and new therapies for the benefit of cancer patients.

  • 2 October 2002

Cancer Research Technology (CRT) is formed through the merger of Cancer Research Ventures (CRV) and Imperial Cancer Research Technology (ICRT), the respective technology transfer companies of the Cancer Research Campaign and the Imperial Cancer Research Fund who themselves merged on February 4, 2002, to become Cancer Research UK.

Harpal Kumar has been appointed as Chief Executive. David Newbigging, Deputy Chairman of the Council of Cancer Research UK, has been appointed non-executive Chairman and it is intended that Melanie Lee, who is a non-executive Director of CRT and Research and Development Director of Celltech plc, will succeed him in due course.

Related content

Two woman speak to each other on an inside balcony, with the photo taken from the floor

Our partnerships

Cancer Research Horizons partners across the fields of academia, industry, drug discovery and investors.

Scientist wearing a white lab coat and goggle looking at some equipment.

Drug discovery and development

We identify, develop and commercialise promising ideas into successful cancer therapeutics, diagnostics and enabling technologies.